Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $15 million versus the consensus estimate of $15.43 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.